More than half a billion people suffer from different forms of cardiovascular disease (CVD) -
the leading cause of mortality in the western world - accounting for over 40% of total deaths. There is an urgent need for novel risk evaluation instruments of CVD patients, as current risk markers in clinical practice are insufficient to guide therapy and the established treatments addressing the known risk factors are inadequate.
Despite current risk assessment and treatment options, 70 % proceed to cardiovascular events. There is a desire to identify risk groups requiring more intensive treatment at earlier stages of disease development, as well as a need for novel therapeutics such as targeted biopharmaceuticals.
Athera is focusing on two targets, with relevance for risk assessment and therapeutic intervention in cardiovascular disease.
Anti-PC Annexin A5